Expertise in
3
conditions

Paolo Bernasconi

Seregno, IT 
Expertise in
3
conditions
Seregno, IT 

Overview

Paolo Bernasconi practices practicing medicine in Seregno, Italy.

Mr. Bernasconi is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Myelofibrosis, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Seregno, Italy
Other Locations
Pavia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
View 1 Less Clinical Trial

62 Total Publications

Enhancing resolution and image quality in musculoskeletal MRI using deep learning reconstruction.
Enhancing resolution and image quality in musculoskeletal MRI using deep learning reconstruction.
Journal: European radiology experimental
Published: November 28, 2025

Frequently Asked Questions about Paolo Bernasconi

Is Paolo Bernasconi a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Paolo Bernasconi is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paolo Bernasconi participate in research or clinical trials?

Yes. Paolo Bernasconi has published 62 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Paolo Bernasconi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bernasconi's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile